88
Participants
Start Date
July 29, 2025
Primary Completion Date
April 30, 2027
Study Completion Date
July 31, 2027
CIT-013 low dose
Subcutaneous injection
CIT-013 high dose
Subcutaneous injection
Placebo
Subcutaneous injection
CIT-013 medium dose
CIT-013 medium dose
NOT_YET_RECRUITING
Site BE-01, Leuven
NOT_YET_RECRUITING
DE-04, Bamberg
NOT_YET_RECRUITING
DE-05, Berlin
NOT_YET_RECRUITING
DE-01, München
NOT_YET_RECRUITING
DE-02, München
NOT_YET_RECRUITING
DE-03, Ratingen
NOT_YET_RECRUITING
NL-02, Amsterdam
NOT_YET_RECRUITING
NL-03, Nijmegen
NOT_YET_RECRUITING
NL-01, Rotterdam
RECRUITING
PL-01, Bialystok
NOT_YET_RECRUITING
PL-03, Lublin
NOT_YET_RECRUITING
PL-02, Poznan
NOT_YET_RECRUITING
PL-05, Torun
NOT_YET_RECRUITING
PL-04, Warsaw
NOT_YET_RECRUITING
ES-02, A Coruña
NOT_YET_RECRUITING
ES-04, Barcelona
NOT_YET_RECRUITING
ES-05, Barcelona
NOT_YET_RECRUITING
ES-06, Madrid
NOT_YET_RECRUITING
ES-01, Santander
NOT_YET_RECRUITING
ES-03, Santiago de Compostela
Lead Sponsor
Citryll BV
INDUSTRY